Manidipina Pharmacare (Manidipine Dihydrochloride)

Manidipine is a calcium channel blocker indicated for the treatment of hypertension, a condition characterized by elevated arterial pressure.

• Essential hypertension: reduces both systolic and diastolic blood pressure.
• Isolated systolic hypertension: helps achieve target systolic pressure.
• Diastolic hypertension: contributes to lowering diastolic pressure.

• Manidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells, inhibiting calcium influx required for muscle contraction. This causes arterial smooth‑muscle relaxation, vasodilation, and a consequent decrease in peripheral vascular resistance, thereby lowering systolic and diastolic blood pressure. Its high affinity for vascular tissue provides antihypertensive effects with minimal impact on cardiac conduction.

Manidipine may be associated with several adverse reactions, ranging from frequent, mild events to rare but serious conditions.

Common Side Effects

• Headache: mild to moderate headache.
• Flushing: transient facial flushing.
• Peripheral edema: swelling of ankles or feet.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing Manidipine, clinicians should consider several precautionary measures to ensure safe use.

• Monitor blood pressure: check regularly after initiation and dose adjustments.
• Assess hepatic function: use with caution in patients with liver impairment.
• Review concomitant antihypertensives: avoid excessive hypotension when combined with other agents.
• Use cautiously in the elderly: increased sensitivity to vasodilatory effects.
• Avoid abrupt discontinuation: taper dose to prevent rebound hypertension.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Manidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase manidipine plasma concentrations.
• Grapefruit juice: can markedly raise drug levels leading to toxicity.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring.
• Beta‑blockers: combined use can increase risk of bradycardia and hypotension.
• ACE inhibitors or ARBs: concurrent therapy may potentiate blood pressure lowering.